Wang Peng, Li Qiu-Ying, Sun Ya-Nan, Wang Jing-Ting, Liu Ming
Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, 150086, Harbin, China.
ORL J Otorhinolaryngol Relat Spec. 2021;83(6):464-470. doi: 10.1159/000515228. Epub 2021 Apr 8.
Laryngeal squamous cell carcinoma (LSCC) is diverse in its natural history and responsiveness to treatments. There is an urgent need to generate candidate biomarkers for the stratification and individualization of treatment to avoid overtreatment or inadequate treatment. Long noncoding RNA nuclear paraspeckle assembly transcript 1 (NEAT1) has been identified as an oncogenic gene in multiple human tumors entitles, and dysregulation of NEAT1 was tightly linked to carcinogenesis and cancer progression.
One hundred two paraffin samples of LSCC patients were collected. Furthermore, in situ hybridization (ISH), Kaplan-Meier, and MTT were used to analyze the relationship between NEAT1 and the progress of LSCC.
In this study, ISH revealed that NEAT1 was strongly expressed in the nucleus. The increased expression of NEAT1 was correlated with T grade, neck nodal metastasis, clinical stage, drinking history, or smoking history of LSCC. The Kaplan-Meier analysis indicated that patients with higher NEAT1 expression had a worse overall survival in LSCC patients. In addition, NEAT1 knockdown significantly inhibited the growth of LSCC cells.
Together, these results suggested that NEAT1 involved in the progress of LSCC and might act as a tumor oncogenic gene. This study provides a potential new marker and target for gene therapy in the treatment of LSCC.
喉鳞状细胞癌（LSCC）的自然病史和对治疗的反应具有多样性。迫切需要生成用于治疗分层和个体化的候选生物标志物，以避免过度治疗或治疗不足。长链非编码RNA核旁斑组装转录本1（NEAT1）已被确定为多种人类肿瘤中的致癌基因，NEAT1的失调与肿瘤发生和癌症进展密切相关。
收集102例LSCC患者的石蜡样本。此外，采用原位杂交（ISH）、Kaplan-Meier法和MTT法分析NEAT1与LSCC进展的关系。
在本研究中，ISH显示NEAT1在细胞核中高表达。NEAT1表达增加与LSCC的T分级、颈部淋巴结转移、临床分期、饮酒史或吸烟史相关。Kaplan-Meier分析表明，NEAT1表达较高的LSCC患者总生存期较差。此外，敲低NEAT1可显著抑制LSCC细胞的生长。
总之，这些结果表明NEAT1参与LSCC的进展，可能作为肿瘤致癌基因。本研究为LSCC治疗提供了一个潜在的新标志物和基因治疗靶点。
